A hyperfractionated radiation therapy (HFX RT) trial (1.2 Gy twice daily, b.i.d.) (HFX) for @entity1149 ( @entity1149 ) showed that 69.6 Gy resulted in better survival than did lower total doses (Radiation Therapy Oncology Group, RTOG 83-11) and that @entity900 concurrent with irradiation improved local control and survival over RT alone (Radiation Therapy Oncology Group, RTOG 91-06). Concurrent combination chemotherapy and HFX could improve both local and systemic control. In a phase II trial (RTOG 91-06) for inoperable @entity1149 , two cycles of PE were used [ @entity900 50 mg/m2 intravenously (i.v.) days 1 and 8, @entity2879 50 mg orally (p.o.) b.i.d., 75 mg/day if body surface area (BSA) < 1.7 m2, days 1-14] starting on day 1 of HFX (69.6 Gy) and repeated on day 29. HFX/PE was compared with HFX (69.6 Gy) from an earlier phase II trial (RTOG 83-11). Seventy-six @entity1 treated with HFX/PE and 203 @entity1 who received HFX alone were compared for @entity137 , response, survival, and patterns of failure. The rates of grade 4 nonhematologic @entity137 were similar (3.0% for HFX/PE, 3.0% for HFX), but grade 4 @entity1503 occurred only with HFX/PE 56.6%. Three (3.9%) HFX/PE @entity1 had fatal @entity137 (2 pulmonary, 1 renal); 1 HFX @entity1 had fatal @entity137 . Response and @entity3 rates were similar for the two treatments, but infield (p = 0.054) and overall (p = 0.04) progression-free survival rates were better with HFX/PE. Median survivals were 18.9 months with HFX/PE and 10.6 months with HFX. Two-year survival rates were 36% for HFX/PE and 22% for HFX (p = 0.014). The differences in survival between HFX/PE and HFX remained borderline statistically significant (p = 0.0593) in the multivariate model, which included @entity353 , Karnofsky performance status (KPS), sex, and stage. HFX/PE is an effective regimen in @entity1 with inoperable @entity1149 , although it is considerably more toxic, and is undergoing a comparison in a three-arm randomized phase III study against induction @entity900 / @entity5713 plus standard once-daily RT and against @entity900 / @entity5713 concurrent with standard RT.

Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced @entity1149 ( XXXX ): comparison of RTOG 83-11 and RTOG 91-06.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'esophageal toxicity'] @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['hematologic toxicity'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity5713 :: ('MESH:D014747', 'Chemical') :: ['vinblastine']
@entity1149 :: (MESH:D002289,Disease) :: ['NSCLC']
